Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Manegold

Showing results (121-130 of 177) with videos related to

Pageof 18
Sort By:
European Heart Journal|June 16, 2007
External cardioversion of atrial fibrillation in patients with implanted pacemaker or cardioverter-defibrillator systems: a randomized comparison of monophasic and biphasic shock energy applicationJohannes C Manegold, Carsten W Israel, Joachim R Ehrlich, et al.
Lung Cancer (Amsterdam, Netherlands)|June 22, 2006
Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancerS Baka, C Manegold, E Buchholz, et al.
Endoscopy|February 26, 2000
Thermoplastic stents: a new concept for endoluminal prosthesisS Freudenberg, M Hartel, F Fernandez, et al.
Journal of Inherited Metabolic Disease|January 28, 2009
Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-upC Manegold, G F Hoffmann, I Degen, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2006
Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984)B Biesma, C Manegold, H J M Smit, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2005
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesotheliomaC Manegold, J Symanowski, U Gatzemeier, et al.
International Journal of Cancer|June 19, 2009
The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38Melissa J LaBonte, Philipp C Manegold, Peter M Wilson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2017
Statistical controversies in clinical research: futility analyses in oncology-lessons on potential pitfalls from a randomized controlled trialE Lesaffre, M J Edelman, N H Hanna, et al.
Bone and Mineral|August 1, 1993
Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemiaC Wüster, K H Schöter, D Thiébaud, et al.
Seminars in Oncology|April 16, 1998
Ifosfamide and gemcitabine: a phase II trial in advanced inoperable non-small cell lung cancerU Gatzemeier, C Manegold, W Eberhard, et al.
Pageof 18

Showing results (121-130 of 177) with videos related to

Sort By:
Pageof 18
European Heart Journal|June 16, 2007
External cardioversion of atrial fibrillation in patients with implanted pacemaker or cardioverter-defibrillator systems: a randomized comparison of monophasic and biphasic shock energy applicationJohannes C Manegold, Carsten W Israel, Joachim R Ehrlich, et al.
Lung Cancer (Amsterdam, Netherlands)|June 22, 2006
Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancerS Baka, C Manegold, E Buchholz, et al.
Endoscopy|February 26, 2000
Thermoplastic stents: a new concept for endoluminal prosthesisS Freudenberg, M Hartel, F Fernandez, et al.
Journal of Inherited Metabolic Disease|January 28, 2009
Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-upC Manegold, G F Hoffmann, I Degen, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2006
Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984)B Biesma, C Manegold, H J M Smit, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2005
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesotheliomaC Manegold, J Symanowski, U Gatzemeier, et al.
International Journal of Cancer|June 19, 2009
The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38Melissa J LaBonte, Philipp C Manegold, Peter M Wilson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2017
Statistical controversies in clinical research: futility analyses in oncology-lessons on potential pitfalls from a randomized controlled trialE Lesaffre, M J Edelman, N H Hanna, et al.
Bone and Mineral|August 1, 1993
Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemiaC Wüster, K H Schöter, D Thiébaud, et al.
Seminars in Oncology|April 16, 1998
Ifosfamide and gemcitabine: a phase II trial in advanced inoperable non-small cell lung cancerU Gatzemeier, C Manegold, W Eberhard, et al.
Pageof 18